By / November 30, 2020

New study from rheumatism research on cannabis consumption

A promising new French study for cannabis use in patients with rheumatism has been published in a journal for rheumatism research. In a systematic evaluation of the medical records concerning the use of hemp, it was found that on average a upwards of 17% of all people affected by rheumatism consumed cannabis to get relief. It was especially effective for those seeking relief from unbearable pain and the chronic inflammation typical of the disease.

Various forms of rheumatism, which are difficult to treat with the usual methods from conventional medicine, are considered in the study. Although strong pharmaceuticals exists in many forms, and the pain may stop for the moment, the prescribed tablets also have strong side effects. Worse still they often do not help at all with the causes of such complaints, which are not yet fully understood anyway.

To follow the latest findings on medical application of cannabis for rheumatism patients, or to stay up to date with medical research and cannabis news, download our companion Hemp.IM app.

Rheumatism patients in search of healing power from the cannabis plant

First of all, it is important to know that the study was not a tiny laboratory test, but a comparison of the data of more than 10,000 French rheumatism patients. Of these 2900 people took advantage of the therapeutic use of cannabis to alleviate symptoms. This despite hemp being prohibited in all its forms in the French Fifth Republic, from Paris to Marseilles. Among others, the following variants of rheumatism were compared:

  • Lupus,
  • Spondylitis,
  • Fibromyalgia and
  • classic rheumatoid arthritis.

All patients at least tried the pills or tinctures from orthodox medicine, but most experienced little improvement or could not stand the strong side effects.Whereas 17%, despite legal barriers, reported positive improvement under cannabis use.

While critics might point out that self reported statistics are hardly reliable, it is worth noting that cannabis proved effective even without the regulations of medical use. Advantages like standardized doses, regular prescription,  or quality assurances that legalization would provide would be more than welcome.

Rheumatism study highlights need for more open cannabis regulations

The insufficient legal situation is repeatedly pointed out by the study, since the potentially helpful substance is explicitly not allowed, despite the affected person’s wishes. Here, in the opinion of the researchers, politicians would be urgently called upon to promote studies and to improve the suffering of the patients with a reasonable cannabis legislation.

When almost 20% of the patients have a positive experience and less pain without reporting any of the problematic side effects sometimes caused by the pharmaceuticals, then this must be a wake-up call for a thorough, scientifically based integration of hemp in pain therapy.

Fibromyalgia reveals the great advantages of cannabis medicine

Further in the article it is explained that while many patients who have fallen ill with Fibromyalgia reported faster pain relief with cannabis use. This complements other studies on hemp use for rheumatism with similar positive results.

If we compare at this point the significant suffering from such illnesses for patients as well as their families, not to mention the enormous costs for the public health system, with the possibility for pain relief through cannabis prescription, then an immediate legalization is actually inevitable in opinion of the researchers. Cannabis is well tolerated, is inexpensive to produce, yet remains quite versatile in its effect profile depending on the cannabis variety, and that’s the scientists talking!

A final word from the world of cannabis research for politicians:

Politicians should take better care of people with rheumatic diseases. According to the results of this new study, they could be helped quickly, simply and without complications. All it would take is if in France, but also in Germany, those directly responsible in politics, such as Jens Spahn or Angela Merkel, finally had more attention for the interest and well-being of the affected patients.

Unfortunately, this has not been the case with cannabis so far, due to outdated legislation or simple scaremongering. Like many other groups of the population, from teenagers to pensioners, the rheumatism patients suffer from such ignorant political inactivity. Hemp is, in the scientific community, seen neither an evil “narcotic” nor an ineffective ‘herbal remedy’, but deserves to be comprehensively researched and made available soon for the self-evident health benefits that are needed by rheumatism patients throughout the  EU.


Featured image by Jonathan Borba via Unsplash)

This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in THC guide, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.